Transient neonatal myasthenia gravis following maternal myasthenia gravis presenting in pregnancy after treatment with Alemtuzumab

Ojectives: Transient neonatal Myasthenia gravis is a postsynaptic neuromuscular junction disorder seen in 10-21% of infants born to mothers with myasthenia gravis. Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of multiple sclerosis. The possibility of developing Myasthenia gravis in a pregnant mother treated with Alemtuzumab is rare. Case presentation: We report a case of transient neonatal myasthenia gravis following treatment with Alemtuzumab for multiple sclerosis in the mother. Conclusions: Therapy with Alemtuzumab increases the risk of secondary autoimmune diseases including Myasthenia gravis.